10-Q Filing

Processa Pharmaceuticals, Inc. CIK: 1533743 Q3 2020

Filing Information

Form Type	10-Q
Accession Number	`0001493152-20-021083`
Period End Date	20200930
Filing Date	20201112
Fiscal Year	2020
Fiscal Period	Q3
XBRL Instance	pcsa-20200930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 77 Income Statement 48 Cash Flow Statement 74 Stockholders Equity 41

Balance Sheet 77 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$691.54K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$325.43K	USD	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	$7.61K	USD	Point-in-time
Due from related party	`DueFromRelatedPartiesCurrent`	-	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$315.61K	USD	Point-in-time
Prepaid expenses and other	`PrepaidExpenseAndOtherAssetsCurrent`	$42.85K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$375.89K	USD	Point-in-time
Total Current Assets	`AssetsCurrent`	$1.01M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$8.93K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$2.60K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Operating lease right-of-use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	$219.07K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	30.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	30.00M	shares	Point-in-time
Operating lease right-of-use assets, net of accumulated amortization	`OperatingLeaseRightOfUseAsset`	$159.20K	USD	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$9.64M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.49M	shares	Point-in-time
Intangible assets, net of accumulated amortization	`IntangibleAssetsNetExcludingGoodwill`	$9.05M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	5.77M	shares	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.77M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	5.49M	shares	Point-in-time
Security deposit	`SecurityDeposit`	$5.54K	USD	Point-in-time
Common stock, shares deemed dividend payable	`CommonStockSharesDeemedDividendPayable`	28,971.00	shares	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$9.87M	USD	Point-in-time
Common stock, shares deemed dividend payable	`CommonStockSharesDeemedDividendPayable`	-	shares	Point-in-time
Total Other Assets	`OtherAssetsNoncurrent`	$9.21M	USD	Point-in-time
Total Assets	`Assets`	$9.59M	USD	Point-in-time
Total Assets	`Assets`	$10.88M	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$802.50K	USD	Point-in-time
Senior convertible notes, net of debt issuance costs	`SeniorNotesCurrent`	$762.23K	USD	Point-in-time
Line of credit payable - related party	`LinesOfCreditCurrent`	-	USD	Point-in-time
Line of credit payable - related party	`LinesOfCreditCurrent`	$700.00K	USD	Point-in-time
Note payable - Paycheck Protection Program, current portion	`NotesPayableCurrent`	$90.33K	USD	Point-in-time
Note payable - Paycheck Protection Program, current portion	`NotesPayableCurrent`	-	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$79.77K	USD	Point-in-time
Current maturities of operating lease liability	`OperatingLeaseLiabilityCurrent`	$77.99K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$21.90K	USD	Point-in-time
Accrued interest	`InterestPayableCurrent`	$89.70K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$75.61K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$427.45K	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$316.00	USD	Point-in-time
Due to related parties	`DueToRelatedPartiesCurrent`	$110.80K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$213.24K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$397.60K	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$1.19M	USD	Point-in-time
Total Current Liabilities	`LiabilitiesCurrent`	$2.66M	USD	Point-in-time
Note payable - Paycheck Protection Program	`NotesPayable`	$72.13K	USD	Point-in-time
Note payable - Paycheck Protection Program	`NotesPayable`	-	USD	Point-in-time
Non-current operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$147.39K	USD	Point-in-time
Non-current operating lease liability	`OperatingLeaseLiabilityNoncurrent`	$86.74K	USD	Point-in-time
Net deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$1.53M	USD	Point-in-time
Net deferred tax liability	`DeferredIncomeTaxLiabilitiesNet`	$1.25M	USD	Point-in-time
Total Liabilities	`Liabilities`	$4.06M	USD	Point-in-time
Total Liabilities	`Liabilities`	$2.87M	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and Contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, par value $0.0001, 30,000,000 and 100,000,000 shares authorized; 5,765,566 and 5,486,595 issued and outstanding at September 30, 2020 and December 31, 2019	`CommonStockValue`	$549.00	USD	Point-in-time
Common stock, par value $0.0001, 30,000,000 and 100,000,000 shares authorized; 5,765,566 and 5,486,595 issued and outstanding at September 30, 2020 and December 31, 2019	`CommonStockValue`	$577.00	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$21.19M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$18.99M	USD	Point-in-time
Common stock deemed dividend payable: 28,971 shares at par value	`CommonStockDeemedDividendPayable`	$3.00	USD	Point-in-time
Common stock deemed dividend payable: 28,971 shares at par value	`CommonStockDeemedDividendPayable`	-	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-15.66M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-10.98M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.67M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$5.53M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$7.23M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$6.59M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.50M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.12M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$9.70M	USD	Point-in-time
Total Stockholders' Equity	`StockholdersEquity`	$8.01M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$10.88M	USD	Point-in-time
Total Liabilities and Stockholders' Equity	`LiabilitiesAndStockholdersEquity`	$9.59M	USD	Point-in-time

Income Statement 48 line items

Line Item	Tag	Value	Unit	Period
Research and development expenses	`ResearchAndDevelopmentExpense`	$584.98K	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpense`	$1.46M	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$1.80M	USD	3 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpense`	$532.59K	USD	1 Quarter
Acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	-	USD	3 Qtrs
Acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	$2.00M	USD	3 Qtrs
Acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	-	USD	1 Quarter
Acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	$2.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.28M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.22M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$422.96K	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$419.03K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$4.74M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$3.02M	USD	3 Qtrs
Total operating expenses	`OperatingExpenses`	$2.96M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.00M	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-2.96M	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-1.00M	USD	1 Quarter
Operating Loss	`OperatingIncomeLoss`	$-4.74M	USD	3 Qtrs
Operating Loss	`OperatingIncomeLoss`	$-3.02M	USD	3 Qtrs
Other Income (Expense) (Note 5)	`OtherNonoperatingIncomeExpense`	$-2.09K	USD	3 Qtrs
Other Income (Expense) (Note 5)	`OtherNonoperatingIncomeExpense`	$-186.20K	USD	1 Quarter
Other Income (Expense) (Note 5)	`OtherNonoperatingIncomeExpense`	$-768.00	USD	1 Quarter
Other Income (Expense) (Note 5)	`OtherNonoperatingIncomeExpense`	$-221.80K	USD	3 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.14M	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-4.97M	USD	3 Qtrs
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.00M	USD	1 Quarter
Net Operating Loss Before Income Tax Benefit	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-3.03M	USD	3 Qtrs
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-286.42K	USD	3 Qtrs
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-442.15K	USD	3 Qtrs
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-141.25K	USD	1 Quarter
Income Tax Benefit	`IncomeTaxExpenseBenefit`	$-70.46K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-3.07M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-4.68M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-2.58M	USD	3 Qtrs
Net Loss	`NetIncomeLoss`	$-874.34K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-733.41K	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-863.52K	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.47	USD	3 Qtrs
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.55	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.16	USD	1 Quarter
Net Loss per Common Share - Basic and Diluted	`EarningsPerShareBasicAndDiluted`	$-0.84	USD	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.53M	shares	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.54M	shares	3 Qtrs
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.59M	shares	1 Quarter
Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	5.53M	shares	1 Quarter

Cash Flow Statement 74 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-3.07M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.68M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-2.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-874.34K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-733.41K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-863.52K	USD	1 Quarter
Depreciation	`Depreciation`	$6.33K	USD	3 Qtrs
Depreciation	`Depreciation`	$6.33K	USD	3 Qtrs
Non-cash lease expense for right-of-use assets	`OperatingLeaseExpense`	$59.88K	USD	3 Qtrs
Non-cash lease expense for right-of-use assets	`OperatingLeaseExpense`	$55.01K	USD	3 Qtrs
Non-cash acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	-	USD	3 Qtrs
Non-cash acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	$2.00M	USD	3 Qtrs
Non-cash acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	-	USD	1 Quarter
Non-cash acquisition of in-process research and development	`ResearchAndDevelopmentInProcess`	$2.00M	USD	1 Quarter
Amortization of debt issuance costs (Note 5)	`AmortizationOfFinancingCostsAndDiscounts`	-	USD	3 Qtrs
Amortization of debt issuance costs (Note 5)	`AmortizationOfFinancingCostsAndDiscounts`	$157.13K	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$596.50K	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$596.50K	USD	3 Qtrs
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$198.83K	USD	1 Quarter
Amortization of intangible asset	`AmortizationOfIntangibleAssets`	$198.83K	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-286.42K	USD	3 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-442.15K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$394.16K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$357.04K	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$269.13K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$164.51K	USD	1 Quarter
Prepaid expenses and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-272.75K	USD	3 Qtrs
Prepaid expenses and other	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-37.55K	USD	3 Qtrs
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$59.00K	USD	3 Qtrs
Operating lease liability	`IncreaseDecreaseInOperatingLeaseLiability`	$58.88K	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$8.59K	USD	3 Qtrs
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$67.80K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$351.84K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-227.24K	USD	3 Qtrs
Due (from) to related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-46.65K	USD	3 Qtrs
Due (from) to related parties	`IncreaseDecreaseInDueFromRelatedParties`	$-102.88K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$30.37K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$184.36K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.14M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-867.84K	USD	3 Qtrs
Proceeds received in satisfaction of stock subscription receivable	`ProceedsFromIssuanceSubscriptionReceivable`	-	USD	3 Qtrs
Proceeds received in satisfaction of stock subscription receivable	`ProceedsFromIssuanceSubscriptionReceivable`	$900.00K	USD	3 Qtrs
Borrowings on line of credit from a related party	`BorrowingsOnLineOfCreditPayableFromRelatedParty`	$700.00K	USD	3 Qtrs
Borrowings on line of credit from a related party	`BorrowingsOnLineOfCreditPayableFromRelatedParty`	-	USD	3 Qtrs
Proceeds received from our Paycheck Protection Program note payable	`ProceedsFromNotesPayable`	-	USD	3 Qtrs
Proceeds received from our Paycheck Protection Program note payable	`ProceedsFromNotesPayable`	$162.46K	USD	3 Qtrs
Transaction costs related to subsequent common stock offering	`TransactionCostsRelatedToSubsequentCommonStockOffering`	$360.73K	USD	3 Qtrs
Transaction costs related to subsequent common stock offering	`TransactionCostsRelatedToSubsequentCommonStockOffering`	-	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$501.73K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$900.00K	USD	3 Qtrs
Net Decrease in Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-366.11K	USD	3 Qtrs
Net Decrease in Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.24M	USD	3 Qtrs
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$504.30K	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$691.54K	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$325.43K	USD	Point-in-time
Cash and Cash Equivalents - Beginning of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$504.30K	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$691.54K	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$325.43K	USD	Point-in-time
Cash and Cash Equivalents - End of Period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$1.74M	USD	Point-in-time
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	$293.20K	USD	3 Qtrs
Right-of-use asset obtained in exchange for operating lease liability	`RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability`	-	USD	3 Qtrs
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	-	USD	3 Qtrs
Reduction in deferred lease liability	`ReductionInDeferredLeaseLiability`	$-9.96K	USD	3 Qtrs
Operating lease liability	`OperatingLeaseLiabilities`	$303.16K	USD	3 Qtrs
Operating lease liability	`OperatingLeaseLiabilities`	-	USD	3 Qtrs
Net	`NonCashleaseLiabilityNet`	-	USD	3 Qtrs
Net	`NonCashleaseLiabilityNet`	-	USD	3 Qtrs
Issuance of 250,000 shares of common stock for the acquisition of in-process research and development in connection with the Yuhan License Agreement	`IssuanceOfCommonStockForAcquisitions`	-	USD	3 Qtrs
Issuance of 250,000 shares of common stock for the acquisition of in-process research and development in connection with the Yuhan License Agreement	`IssuanceOfCommonStockForAcquisitions`	$2.00M	USD	3 Qtrs
Issuance of 28,971 shares of common stock due to triggering, in December 2019, the full ratchet anti-dilution provision of common stock sold in our 2018 Private Placement Transactions	`IssuanceOfCommonStockDueToTriggering`	-	USD	3 Qtrs
Issuance of 28,971 shares of common stock due to triggering, in December 2019, the full ratchet anti-dilution provision of common stock sold in our 2018 Private Placement Transactions	`IssuanceOfCommonStockDueToTriggering`	$3.00	USD	3 Qtrs

Stockholders Equity 41 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$8.67M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.53M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.23M	USD	Point-in-time
Balance	`StockholdersEquity`	$6.59M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.50M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.12M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.01M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$58.56K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$66.48K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$93.87K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$164.51K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$269.13K	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$98.66K	USD	1 Quarter
Payments made directly by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$280.93K	USD	1 Quarter
Payments made directly by investor for clinical trial costs	`AdjustmentsToAdditionalPaidInCapitalPaymentMadeByInvestorForClinicalTrialCosts`	$115.00K	USD	1 Quarter
Conversion of Senior convertible notes for common stock and stock purchase warrants	`StockIssuedDuringPeriodValueConversionOfUnits`	$258.93K	USD	1 Quarter
Payments/reimbursements made by investor for clinical trial costs	`AdjustmentToAdditionalPaidInCapitalPaymentsreimbursementsMadeByInvestorForClinicalTrialCosts`	$504.07K	USD	1 Quarter
Pledged shares of common stock forfeited upon revised agreement with clinical trial investor	`PledgedSharesOfCommonStockForfeitedUponRevisedAgreementWithClinicalTrialInvestor`	-	USD	1 Quarter
Transaction costs related to anticipated 2020 offering	`AdjustmentToAdditionalPaidInCapitalTransactionCostsRelatedToAnticipatedOffering`	$-1.51K	USD	1 Quarter
Transaction costs related to anticipated 2020 offering	`AdjustmentToAdditionalPaidInCapitalTransactionCostsRelatedToAnticipatedOffering`	$-356.42K	USD	1 Quarter
Transaction costs related to anticipated 2020 offering	`AdjustmentToAdditionalPaidInCapitalTransactionCostsRelatedToAnticipatedOffering`	$-2.81K	USD	1 Quarter
Stock dividend distributed due to full-ratchet anti-dilution adjustment	`StockDividendDistributedDueToFullratchetAntidilutionAdjustment`	-	USD	1 Quarter
Shares issued in connection with Yuhan license agreement	`StockIssuedDuringPeriodValueOther`	$2.00M	USD	1 Quarter
Fair value of warrants issued in the sale of our 2019 Senior Notes	`DebtIssuanceCostsAttributedToWarrantsIssuedInSaleOfSeniorNotes`	$197.40K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-3.07M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-969.08K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-4.68M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-2.58M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-874.34K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-750.83K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-733.41K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-863.52K	USD	1 Quarter
Balance	`StockholdersEquity`	$8.67M	USD	Point-in-time
Balance	`StockholdersEquity`	$5.53M	USD	Point-in-time
Balance	`StockholdersEquity`	$7.23M	USD	Point-in-time
Balance	`StockholdersEquity`	$6.59M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.50M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.12M	USD	Point-in-time
Balance	`StockholdersEquity`	$9.70M	USD	Point-in-time
Balance	`StockholdersEquity`	$8.01M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.